These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 30358185)

  • 1. Histone deacetylase inhibitors as a new anticancer option: How far can we go with expectations? delivery systems.
    Garmpi A; Garmpis N; Damaskos C; Valsami S; Spartalis E; Lavaris A; Patelis N; Margonis GA; Apostolou KG; Spartalis M; Andreatos N; Diamantis E; Tsivelekas K; Moschos MM; Nonni A; Tsourouflis G; Markatos K; Antoniou EA; Kontzoglou K; Nikiteas N; Dimitroulis D
    J BUON; 2018; 23(4):846-861. PubMed ID: 30358185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone Deacetylase Inhibitors as Anticancer Drugs.
    Eckschlager T; Plch J; Stiborova M; Hrabeta J
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
    Emanuele S; Lauricella M; Tesoriere G
    Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
    Cappellacci L; Perinelli DR; Maggi F; Grifantini M; Petrelli R
    Curr Med Chem; 2020; 27(15):2449-2493. PubMed ID: 30332940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
    Chun P
    Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
    Singh AK; Bishayee A; Pandey AK
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in histone deacetylase targeted cancer therapy.
    Hoshino I; Matsubara H
    Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
    Jazirehi AR
    Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
    Apuri S; Sokol L
    Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.
    Tinari N; De Tursi M; Grassadonia A; Zilli M; Stuppia L; Iacobelli S; Natoli C
    Curr Cancer Drug Targets; 2012 May; 12(4):439-52. PubMed ID: 22309455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat.
    Zagni C; Floresta G; Monciino G; Rescifina A
    Med Res Rev; 2017 Nov; 37(6):1373-1428. PubMed ID: 28181261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer.
    Damaskos C; Garmpis N; Karatzas T; Nikolidakis L; Kostakis ID; Garmpi A; Karamaroudis S; Boutsikos G; Damaskou Z; Kostakis A; Kouraklis G
    Anticancer Res; 2015 Jun; 35(6):3129-35. PubMed ID: 26026072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors in the treatment of lymphoma.
    Lemoine M; Younes A
    Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
    Amin SA; Adhikari N; Jha T
    Pharmacol Res; 2018 May; 131():128-142. PubMed ID: 29514055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
    Cheng T; Grasse L; Shah J; Chandra J
    Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Histone deacetylase inhibitors - molecular mechanisms of actions and clinical applications].
    Grabarska A; Dmoszyńska-Graniczka M; Nowosadzka E; Stepulak A
    Postepy Hig Med Dosw (Online); 2013 Aug; 67():722-35. PubMed ID: 24018438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics and histone deacetylase inhibitors.
    Goey AK; Sissung TM; Peer CJ; Figg WD
    Pharmacogenomics; 2016 Nov; 17(16):1807-1815. PubMed ID: 27767376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from NETosis to Apoptosis.
    Hamam HJ; Palaniyar N
    Biomolecules; 2019 May; 9(5):. PubMed ID: 31083537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas.
    Manta A; Kazanas S; Karamaroudis S; Gogas H; Ziogas DC
    Oncol Res; 2022; 30(5):211-219. PubMed ID: 37305348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.